Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene

Blood

Volumn 109, Issue 9, 2007, Pages 4089-4096

  Van Bergen, Cornelis A M ^a   Kester, Michel G D ^a   Jedema, Inge ^a   Heemskerk, Mirjam H M ^a   Van Luxemburg Heijs, Simone A P ^a   Kloosterboer, Freke M ^a   Marijt, W A Erik ^a   De Ru, Arnoud H ^a   Schaafsma, M Ron ^b   Willemze, Roel ^a   Van Veelen, Peter A ^a   Falkenburg, J H Frederik ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MINOR HISTOCOMPATIBILITY ANTIGEN; TETRAMER;

ACUTE GRAFT VERSUS HOST DISEASE; ANTIGEN EXPRESSION; ARTICLE; ATP DEPENDENT INTERFERON RESPONSIVE GENE; B LYMPHOCYTE; CELL ACTIVATION; CELL ISOLATION; CHEMICAL ANALYSIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; FLUORESCENCE ACTIVATED CELL SORTING; GENE; GENE EXPRESSION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MASS SPECTROMETRY; MULTIPLE MYELOMA; PEPTIDE ANALYSIS; PRIORITY JOURNAL; RELAPSE; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TUMOR CELL;

EID: 34247385455     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-08-043935     Document Type: Article

References (46)

1. Appelbaum FR. The current status of hematopoietic cell transplantation. Annu Rev Med. 2003;54: 491-512.
2. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
3. Barrett AJ. Mechanisms of the graft-versus-leukemia reaction. Stem Cells. 1997;15:248-258.
4. Riddell SR, Berger C, Murata M, Randolph S, Warren EH. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev. 2003;17:153-162.
5. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer. 2004;4:371-380.
6. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80: 2964-2968.
7. Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev. 2003;17: 187-194.
8. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988;108:806-814.
9. Apperley JF, Mauro FR, Goldman JM, et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol. 1988;69:239-245.
10. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78:2120-2130.
11. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.
12. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
13. Porter DL, Collins RH, Hardy C, et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood. 2000;95:1214-1221.
14. Barge RM, Osanto S, Marijt WA, et al. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. Exp Hematol. 2003;31:865-872.
15. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103:767-776.
16. Barge RM, Osanto S, Marijt WA, et al. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. Exp Hematol. 2003;31:865-872.
17. Posthuma EF, Marijt EW, Barge RM, et al. Alphainterferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Biol Blood Marrow Transplant. 2004;10:204-212.
18. Barge RMY, Starrenburg CW, Falkenburg JHF, et al. Long term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience. Bone Marrow Transplant. 2006;37:1129-1134.
19. Falkenburg JHF, van de Corput L, Marijt EWA, Willemze R. Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol. 2003;31:743-751.
20. Hambach L, Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol. 2005;17:202-210.
21. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A. 2003;100:2742-2747.
22. Brickner AG, Warren EH, Caldwell JA, et al. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J Exp Med. 2001;193:195-206.
23. Spierings E, Brickner AG, Caldwell JA, et al. The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood. 2003;102:621-629.
24. den Haan JM, Sherman NE, Blokland E, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science. 1995;268:1476-1480.
25. den Haan JM, Meadows LM, Wang W, et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 1998;279:1054-1057.
26. Dolstra H, Fredrix H, Maas F, et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med. 1999; 189:301-308.
27. Akatsuka Y, Nishida T, Kondo E, et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med. 2003;197: 1489-1500.
28. Kloosterboer FM, Luxemburg-Heijs SA, van Soest RA, et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia. 2004;18:798-808.
29. Rijke BD, Horssen-Zoetbrood A, Beekman JM, et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest. 2005;115:3506-3516.
30. Brickner AG, Evans AM, Mito JK, et al. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood. 2006;107:3779-3786.
31. Slager EH, Honders MW, van der Meijden ED, et al. Identification of the angiogenic endothelial cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood. 2006;107:4954-4960.
32. Warren EH, Gavin MA, Xuereb SM, et al. A single nucleotide polymorphism in the SP110 nuclear phosphoprotein gene creates a minor histocompatibility antigen whose expression is regulated by IFN-gamma [abstract]. Blood. 2002;100:73a. Abstract 265.
33. Kloosterboer FM, Luxemburg-Heijs SA, van Soest RA, et al. Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to in-flammatory cytokines: relevance for allogeneic immunotherapy of leukemia. Blood. 2005;106: 3955-3957.
34. Ferrara JL. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol. 1993;5:794-799.
35. Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc. 1993;25:1216-1217.
36. Kloosterboer FM, Luxemburg-Heijs SAP, van Soest RA, et al. Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFN gamma-secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion. Leukemia. 2005;19:83-90.
37. Dron M, Meritet JF, Dandoy-Dron F, et al. Molecular cloning of ADIR, a novel interferon responsive gene encoding a protein related to the torsins. Genomics. 2002;79:315-325.
38. Alexander J, Payne JA, Murray R, Frelinger JA, Cresswell P. Differential transport requirements of HLA and H-2 class I glycoproteins. Immunogenetics. 1989;29:380-388.
39. Heemskerk MH, Hoogeboom M, Hagedoorn R, et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med. 2004;199:885-894.
40. Jedema I, van der Werff NM, Barge RMY, Willemze R, Falkenburg JHF. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood. 2004;103:2677-2682.
41. Faber LM, Luxemburg-Heijs SA, Willemze R, Falkenburg JH. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med. 1992;176:1283-1289.
42. Heemskerk MHM, de Paus RA, Lurvink EGA, et al. Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proc Natl Acad Sci U S A. 2001;98:6806-6811.
43. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96.
44. Arden B, Clarck S, Kabelitz D, Mak T. Human T-cell receptor variable gene segment families. Immunogenetics. 1995;42:455-500.
45. Mensink E, van de LA, Schattenberg A, et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol. 1998;102:768-774.
46. Fowler DH, Foley J, Whit-Shan HJ, et al. Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease. Clin Gastroenterol Hepatol. 2004;2: 237-245.